Short Company
Outlook
Ikonisys is a leading cell-based diagnostics company that markets the proprietary Ikoniscope® Digital Microscope, engineered to provide highly accurate and reliable detection of rare cells. Leveraging advanced molecular and immunological markers, Ikoniscope-built applications are widely used across the US and Europe for diagnosing various cancers. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification.
The Ikoniscope instrument operates through the proprietary Ikonisoft® software system. This highly optimized software manages the Ikoniscope’s robotic components, image acquisition, and cell detection, enabling true hands-off slide handling for continuous, year-round operation.
A suite of oncoFISH® diagnostic applications is built on the Ikonisoft engine, finely tuned for detecting cancer-related chromosomal abnormalities using FISH (Fluorescence In Situ Hybridization). These clinical diagnostic applications are utilized for diagnosing various types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH HER2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK), and a range of hematological cancers using the Explorer applications.
The exceptional ability of the Ikoniscope to detect rare cells is particularly effective in identifying circulating tumor cells (CTC), combining up to six immunofluorescent and FISH markers for comprehensive detection.